tiprankstipranks
Trending News
More News >
EKF Diagnostics Holdings PLC (GB:EKF)
LSE:EKF

EKF Diagnostics Holdings (EKF) AI Stock Analysis

Compare
3 Followers

Top Page

GB

EKF Diagnostics Holdings

(LSE:EKF)

Rating:75Outperform
Price Target:
30.00p
▲(15.38%Upside)
EKF Diagnostics Holdings shows a solid overall performance driven by strong financial health and positive technical indicators. The strategic corporate actions, such as share buybacks and increased major shareholder confidence, also play a significant role. The main risk is the declining revenue trend, which should be monitored closely.
Positive Factors
Cash Flow
Cash generation continues to be very strong, even with selective and planned investments being made.
Financial Performance
EKF reports a positive trading update, with the business on track to meet market expectations for revenues.
Negative Factors
Revenue Decline
FY24 revenues declined 4.6%, which was lower than prior consensus.

EKF Diagnostics Holdings (EKF) vs. iShares MSCI United Kingdom ETF (EWC)

EKF Diagnostics Holdings Business Overview & Revenue Model

Company DescriptionEKF Diagnostics Holdings plc designs, develops, manufactures, and sells diagnostic instruments, reagents, and other ancillary products in Europe, the Middle East, the Americas, Asia, Africa, and internationally. It offers DiaSpect Tm hand-held hemoglobin analyzer; DiaSpect Hemoglobin T analyzer; Hemo Control, a hemoglobin analyzer that provides quantitative and lab quality hemoglobin results; and HemataStat II, a microhematocrit centrifuge that provides a quantitative hematocrit reading for six blood samples. The company also provides glucose and lactate analyzers, such as Biosen C-Line GP+ and C-Line Clinic; Quo-Lab A1c, a desktop point-of-care analyzer for measuring glycated hemoglobin; Quo-Test A1c for the monitoring and management of diabetes; and STAT-Site M Beta-hydroxybutyrate analyzer. In addition, it offers Creamatocrit Plus, an analyzer for detecting the lipid concentration and calorific density in mothers' milk; QuPID and True20 pregnancy tests; and Lactate Scout 4, a lactate analyzer. Further, the company provides clinical chemical analyzers, such as Beta-hydroxybutyrate for monitoring ketosis; Glycated Albumin; Glycated Serum Protein; Nitro-tab Ketone tablets; and Procalcitonin marker for bacterial infection and sepsis, as well as reagents, calibrators, standards, and controls. Additionally, it offers RaPET Serology immunoassay kits; QuStick Strep A for Strep A infection treatment; Altair 240, a chemistry analyzer; Excel, a semi-automated chemistry analyzer; Micro 12, a micro centrifuge for clinical, molecular, and bacteriological applications; Hema-Screen Serology, an analyzer dependent for early detection of colorectal cancer; Uri-Trak 120 urine analyzer; and kits and other services related to COVID-19, as well as contract manufacturing solutions to third-party businesses and laboratory services. The company was founded in 1990 and is headquartered in Cardiff, the United Kingdom.
How the Company Makes MoneyEKF generates revenue through the sale of its diagnostic devices and consumables to healthcare providers and institutions worldwide. The company's key revenue streams include direct sales to healthcare facilities, distribution agreements with partners, and long-term contracts with hospitals and clinics. EKF also engages in strategic partnerships to expand its market reach and enhance its product offerings. Additionally, recurring revenue is generated from the sale of consumables and reagents associated with its diagnostic devices, contributing to a stable financial performance. The company's focus on innovation and expansion into emerging markets further supports its growth and profitability.

EKF Diagnostics Holdings Financial Statement Overview

Summary
EKF Diagnostics Holdings demonstrates solid financial health with strong profit margins and low leverage. Although revenue declined, improved profitability and efficient cost management are positive indicators. Strong balance sheet with minimal debt reduces financial risk, and robust cash flows, despite historical volatility, highlight the company's financial stability.
Income Statement
65
Positive
EKF Diagnostics Holdings has shown a mixed performance in its income statement. The gross profit margin for the latest year is approximately 42.78%, which is solid, but lower revenue growth is concerning. The net profit margin improved significantly from the previous year to 12.43%, indicating a rebound in profitability. However, revenue declined over the years with a negative growth rate of -4.60% from 2023 to 2024. The EBIT and EBITDA margins are healthy at 12.87% and 22.23%, respectively, showing operational efficiency.
Balance Sheet
75
Positive
The balance sheet is quite robust, reflecting a strong equity base with a high equity ratio of 88.49%. The debt-to-equity ratio is very low at 0.02, indicating minimal leverage and reduced financial risk. Return on equity is relatively strong at 8.63%, suggesting effective use of equity to generate profits. However, a downward trend in total assets and stockholders' equity over the years could be a point of concern.
Cash Flow
70
Positive
Cash flow analysis shows a positive trend with operating cash flow comfortably exceeding net income, resulting in a strong operating cash flow to net income ratio of 2.19. Free cash flow has turned positive and grew significantly from the previous year, with a free cash flow to net income ratio of 1.83, reflecting improved cash generation capabilities. However, fluctuations in free cash flow in prior years highlight some volatility.
BreakdownDec 2024Dec 2023Dec 2022Dec 2021Dec 2020
Income Statement
Total Revenue50.19M52.61M66.64M81.84M65.26M
Gross Profit21.48M23.86M24.04M39.37M37.42M
EBITDA11.16M7.68M-2.18M27.39M20.04M
Net Income6.24M2.35M-9.58M15.85M11.11M
Balance Sheet
Total Assets81.75M80.85M89.29M115.12M101.27M
Cash, Cash Equivalents and Short-Term Investments13.01M6.02M11.58M20.34M21.91M
Total Debt1.32M4.10M1.55M2.63M1.58M
Total Liabilities8.53M12.63M14.77M20.38M23.07M
Stockholders Equity72.33M67.12M73.35M94.12M77.65M
Cash Flow
Free Cash Flow11.41M-664.00K3.86M4.59M11.16M
Operating Cash Flow13.66M6.31M9.69M10.24M13.81M
Investing Cash Flow-2.66M-5.64M-8.93M-5.48M1.34M
Financing Cash Flow-4.08M-3.65M-11.04M-6.16M-5.21M

EKF Diagnostics Holdings Technical Analysis

Technical Analysis Sentiment
Positive
Last Price26.00
Price Trends
50DMA
24.67
Positive
100DMA
23.25
Positive
200DMA
25.12
Positive
Market Momentum
MACD
0.39
Positive
RSI
50.33
Neutral
STOCH
18.75
Positive
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For GB:EKF, the sentiment is Positive. The current price of 26 is below the 20-day moving average (MA) of 26.48, above the 50-day MA of 24.67, and above the 200-day MA of 25.12, indicating a neutral trend. The MACD of 0.39 indicates Positive momentum. The RSI at 50.33 is Neutral, neither overbought nor oversold. The STOCH value of 18.75 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for GB:EKF.

EKF Diagnostics Holdings Peers Comparison

Overall Rating
UnderperformOutperform
Sector (51)
Financial Indicators
Name
Overall Rating
Market Cap
P/E Ratio
ROE
Dividend Yield
Revenue Growth
EPS Growth
GBEKF
75
Outperform
£117.66M18.848.95%4.80%-4.59%165.38%
GBIHC
60
Neutral
£20.17M-65.64%-16.51%-1655.56%
GBRUA
55
Neutral
£7.68M1,237.500.08%56.29%
52
Neutral
£54.65M-38.49%
51
Neutral
$7.50B0.32-61.87%2.27%17.10%1.59%
40
Underperform
£42.70M-63.28%1557.07%24.70%
GBKOO
£69.07M8.7831.81%
* Healthcare Sector Average
Performance Comparison
Ticker
Company Name
Price
Change
% Change
GB:EKF
EKF Diagnostics Holdings
26.00
-2.35
-8.29%
GB:RUA
RUA Life Sciences
12.38
1.13
10.04%
GB:CREO
Creo Medical
12.75
-20.00
-61.07%
GB:IHC
Inspiration Healthcare
22.00
4.75
27.54%
GB:SBTX
SkinBioTherapeutics
16.50
7.75
88.57%
GB:KOO
Kooth
193.00
-114.00
-37.13%

EKF Diagnostics Holdings Corporate Events

Stock BuybackBusiness Operations and Strategy
EKF Diagnostics Completes Share Cancellation and Continues Buyback Efforts
Positive
Jun 25, 2025

EKF Diagnostics Holdings plc has completed the cancellation of 5,836,774 ordinary shares, including those previously held in treasury, as part of its share buyback program. This action reduces the company’s total issued share capital to 449,093,790 ordinary shares, which will now serve as the basis for shareholder voting rights calculations. The company continues to pursue additional share buybacks up to approximately £1.0 million, reflecting its strategic focus on optimizing capital structure and enhancing shareholder value.

The most recent analyst rating on (GB:EKF) stock is a Buy with a £0.29 price target. To see the full list of analyst forecasts on EKF Diagnostics Holdings stock, see the GB:EKF Stock Forecast page.

Other
Schroders PLC Increases Stake in EKF Diagnostics Holdings
Positive
Jun 17, 2025

EKF Diagnostics Holdings PLC has announced a significant change in its shareholding structure, with Schroders PLC increasing its stake in the company. This acquisition of shares by Schroders PLC, a major investment firm based in London, raises its total shareholding to over 6%, indicating a vote of confidence in EKF Diagnostics’ market position and future prospects. This development is likely to impact EKF’s market dynamics and could influence investor perceptions positively.

The most recent analyst rating on (GB:EKF) stock is a Buy with a £0.29 price target. To see the full list of analyst forecasts on EKF Diagnostics Holdings stock, see the GB:EKF Stock Forecast page.

Regulatory Filings and Compliance
EKF Diagnostics Announces Total Voting Rights and Share Capital Details
Neutral
Jun 2, 2025

EKF Diagnostics Holdings plc has announced its total issued share capital, consisting of 454,930,564 Ordinary Shares, with 5,836,774 held in treasury, resulting in 449,093,790 shares carrying voting rights. This figure is crucial for shareholders to determine their notification requirements under the FCA’s Disclosure and Transparency Rules, impacting how they manage their investments and compliance obligations.

The most recent analyst rating on (GB:EKF) stock is a Buy with a £0.29 price target. To see the full list of analyst forecasts on EKF Diagnostics Holdings stock, see the GB:EKF Stock Forecast page.

Stock Buyback
EKF Diagnostics Announces Additional Share Buyback Program
Neutral
May 21, 2025

EKF Diagnostics Holdings plc has announced an additional share buyback program following the successful completion of an initial program. The company plans to repurchase up to £1.0 million worth of ordinary shares, which will be held in treasury. This move is facilitated by Harwood Capital Management, ensuring that the aggregate indirect beneficial interest of Christopher Mills, a non-executive director, remains stable. The buyback is structured to avoid triggering a mandatory offer under the City Code on Takeovers and Mergers, thus maintaining the current shareholder structure.

The most recent analyst rating on (GB:EKF) stock is a Buy with a £0.29 price target. To see the full list of analyst forecasts on EKF Diagnostics Holdings stock, see the GB:EKF Stock Forecast page.

Shareholder MeetingsBusiness Operations and Strategy
EKF Diagnostics Secures Unanimous Approval at AGM
Positive
May 20, 2025

EKF Diagnostics Holdings plc announced that all resolutions were passed at its recent Annual General Meeting, indicating strong shareholder support. This outcome reflects positively on the company’s governance and strategic direction, potentially reinforcing its market position and stakeholder confidence.

The most recent analyst rating on (GB:EKF) stock is a Buy with a £0.29 price target. To see the full list of analyst forecasts on EKF Diagnostics Holdings stock, see the GB:EKF Stock Forecast page.

Stock BuybackBusiness Operations and StrategyFinancial Disclosures
EKF Diagnostics Reports Strong Q1 2025 Performance and Strategic Growth
Positive
May 20, 2025

EKF Diagnostics Holdings plc announced positive trading results for the first quarter of 2025, aligning with management expectations. The company has benefited from a streamlined business model focusing on higher-margin products, particularly in Hematology, and has a strong order book for analyzers in Latin America. The Life Sciences division continues to perform well, with robust sales of β-HB and an improved pipeline for contract manufacturing. Cash generation remains strong, supporting growth investments and a successful £1m share buyback program, with expectations for cash levels to exceed those of FY 2024.

The most recent analyst rating on (GB:EKF) stock is a Buy with a £0.29 price target. To see the full list of analyst forecasts on EKF Diagnostics Holdings stock, see the GB:EKF Stock Forecast page.

Stock BuybackBusiness Operations and Strategy
EKF Diagnostics Concludes Share Buyback Program
Positive
May 13, 2025

EKF Diagnostics Holdings plc has successfully completed its share buyback program, purchasing a total of 4,636,774 ordinary shares at an average price of 21.48 pence per share, with the final transaction involving 367,000 shares. This buyback is part of a strategic financial maneuver to manage the company’s capital structure and enhance shareholder value. The completion of this program also involved transactions with Harwood, acting as an investment manager for Oryx International Growth Fund Limited and North Atlantic Smaller Companies Investment Trust PLC, ensuring that Mr. Mills’ aggregate indirect beneficial interest remains stable. The buyback reduces the number of shares in circulation, potentially increasing the value of remaining shares and impacting shareholder voting rights.

The most recent analyst rating on (GB:EKF) stock is a Buy with a £0.29 price target. To see the full list of analyst forecasts on EKF Diagnostics Holdings stock, see the GB:EKF Stock Forecast page.

Stock BuybackBusiness Operations and Strategy
EKF Diagnostics Announces Strategic Share Buyback
Positive
May 9, 2025

EKF Diagnostics Holdings plc has announced the buyback of 992,762 of its ordinary shares at a weighted average price of 21.5 pence per share, which will be held in treasury. This move is part of a strategic effort to manage the company’s share capital and maintain the indirect beneficial interest of Mr. Mills, a significant stakeholder, at approximately the same level, ensuring it does not exceed 30% of the total voting rights. The buyback may impact the company’s market positioning by potentially increasing shareholder value and demonstrating confidence in its financial stability.

Stock BuybackBusiness Operations and Strategy
EKF Diagnostics Announces Strategic Share Buyback
Positive
May 8, 2025

EKF Diagnostics Holdings plc has announced a share buyback, purchasing 709,125 of its ordinary shares at an average price of 21.3519 pence per share, which will be held in treasury. This transaction, which includes a significant purchase from Harwood as investment manager to Oryx International Growth Fund Limited and North Atlantic Smaller Companies Investment Trust PLC, ensures that Mr. Mills’ indirect beneficial interest remains stable, not exceeding 30% of the total voting rights. This strategic move may impact the company’s market positioning by potentially increasing shareholder value and maintaining control over voting rights.

Stock BuybackBusiness Operations and Strategy
EKF Diagnostics Announces Strategic Share Buyback
Neutral
May 6, 2025

EKF Diagnostics Holdings plc announced the buyback of 177,279 of its ordinary shares at a price of 21 pence per share, which will be held in treasury. This transaction is part of a strategic move to manage its share capital and maintain the aggregate indirect beneficial interest of Mr. Mills, a significant shareholder, at approximately the same level, ensuring it does not exceed 30% of the total voting rights. This buyback could impact the company’s shareholding structure and influence shareholder decisions regarding their interests in the company.

Stock BuybackBusiness Operations and Strategy
EKF Diagnostics Announces Share Buyback to Manage Capital Structure
Positive
Apr 29, 2025

EKF Diagnostics Holdings plc has announced the purchase of 200,000 of its ordinary shares at a price of 21 pence per share, which will be held in treasury. This share buyback is part of the company’s strategy to manage its capital structure and maintain the aggregate indirect beneficial interest of Mr. Mills, a non-executive director, at approximately the same level, ensuring it does not exceed 30% of the total voting rights. This move may impact the company’s market positioning by potentially increasing shareholder value and stabilizing its share price.

Stock BuybackBusiness Operations and Strategy
EKF Diagnostics Announces Strategic Share Buyback
Positive
Apr 29, 2025

EKF Diagnostics Holdings plc announced a share buyback, purchasing 200,000 ordinary shares at 21 pence each, which will be held in treasury. This move is part of a strategic effort to manage the company’s capital structure and maintain the aggregate indirect beneficial interest of Mr. Mills, a significant stakeholder, at a stable level. The buyback reflects EKF’s commitment to optimizing shareholder value and may impact the company’s market positioning by potentially increasing share value and demonstrating financial stability.

Shareholder MeetingsFinancial Disclosures
EKF Diagnostics Publishes 2024 Annual Report and Announces 2025 AGM
Neutral
Apr 28, 2025

EKF Diagnostics Holdings plc has published its Annual Report and Accounts for the year ending December 31, 2024, along with the notice for its 2025 Annual General Meeting (AGM). The AGM is scheduled for May 20, 2025, in London, with provisions for shareholders to participate online or via phone. The company encourages shareholders to vote online and submit questions in advance, streamlining the process for engagement and decision-making.

Stock BuybackBusiness Operations and Strategy
EKF Diagnostics Announces Share Buyback to Optimize Capital Structure
Neutral
Apr 9, 2025

EKF Diagnostics Holdings plc has announced the buyback of 570,915 of its ordinary shares at a weighted average price of 21 pence per share, which will be held in treasury. This move is part of a strategic effort to manage the company’s share capital and maintain the aggregate indirect beneficial interest of key stakeholders, such as Mr. Mills, at a stable level. The buyback is expected to impact the company’s total voting rights, with the new total number of ordinary shares carrying voting rights being 451,539,956. This announcement reflects EKF’s ongoing commitment to optimizing its capital structure and ensuring compliance with regulatory requirements.

Stock BuybackBusiness Operations and Strategy
EKF Diagnostics Announces Share Buyback to Optimize Capital Structure
Positive
Apr 8, 2025

EKF Diagnostics Holdings plc has announced the repurchase of 500,000 of its ordinary shares at a price of 21 pence per share, which will be held in treasury. This buyback is part of a strategic move to manage the company’s share capital and maintain shareholder value. The transaction included acquiring shares from Harwood as investment manager to Oryx, ensuring that Mr. Mills’ aggregate indirect beneficial interest remains stable. This action reflects EKF’s ongoing efforts to optimize its capital structure and potentially enhance its market positioning.

Stock BuybackBusiness Operations and Strategy
EKF Diagnostics Announces Strategic Share Buyback
Positive
Apr 7, 2025

EKF Diagnostics Holdings plc announced a share buyback of 278,000 ordinary shares at a weighted average price of 22.5 pence per share, which will be held in treasury. This move is part of a strategic effort to manage the company’s share capital and maintain the aggregate indirect beneficial interest of Mr. Mills, a non-executive director, at approximately the same level, ensuring it does not exceed 30% of the total voting rights. This buyback reflects EKF’s ongoing commitment to optimizing shareholder value and maintaining a balanced capital structure.

Stock BuybackBusiness Operations and Strategy
EKF Diagnostics Announces Share Buyback to Strengthen Market Position
Neutral
Apr 7, 2025

EKF Diagnostics Holdings plc has announced the buyback of 278,000 of its ordinary shares at a weighted average price of 22.5 pence per share, which will be held in treasury. This move impacts the company’s total voting rights, now consisting of 452,610,871 shares, and is part of a strategy to maintain shareholder interests, particularly that of Mr. Mills, whose indirect beneficial interest remains stable. The buyback reflects EKF’s ongoing efforts to manage its capital structure and maintain its market position.

Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: Jun 25, 2025